New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia
- 1 October 2004
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 127 (2), 127-139
- https://doi.org/10.1111/j.1365-2141.2004.05143.x
Abstract
Osteoporosis represents an important cause of morbidity in adult patients with thalassaemia major (TM). The pathogenesis of osteoporosis in TM is multifactorial, and includes bone marrow expansion, endocrine dysfunction and iron overload. Additional genetic factors, such as the COLIA 1 gene polymorphism, seem to play an important role in the development of low bone mass in these patients. However, the mechanisms through which these factors lead to bone loss have not been completely clarified. The diminished osteoblast function is accompanied by a comparable or even greater increase in osteoclast activity. The receptor activator of nuclear factor-kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway has been recently recognized as the final, dominant mediator of osteoclast proliferation and activation. There is increased evidence that this pathway interferes in the pathogenesis of thalassaemia-induced osteoporosis. Currently, bisphosphonates that are potent inhibitors of osteoclast function have been used in TM patients with encouraging results. This review attempts to summarize all the novel data for the biology of bone damage in TM. It also describes the results of all major studies that have investigated the effects of different treatment modalities for TM-induced osteoporosis, their mode of action, and the future implications of their use.This publication has 104 references indexed in Scilit:
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugsJournal of Bone and Mineral Metabolism, 2004
- Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosisJournal of Bone and Mineral Metabolism, 2003
- Importance of Membrane- or Matrix-Associated Forms of M-CSF and RANKL/ODF in Osteoclastogenesis Supported by SaOS-4/3 Cells Expressing Recombinant PTH/PTHrP ReceptorsJournal of Bone and Mineral Research, 2000
- Transforming Growth Factor-β1 Gene Polymorphism, Bone Turnover, and Bone Mass in Italian Postmenopausal WomenJournal of Bone and Mineral Research, 2000
- Iron Deposition in the Anterior Pituitary in Homozygous Beta-Thalassemia: MRI Evaluation and Correlation with Gonadal FunctionJournal of Pediatric Endocrinology and Metabolism, 2000
- Polymorphisms of the Calcitonin Receptor Gene Are Associated with Bone Mineral Density in Postmenopausal Italian WomenBiochemical and Biophysical Research Communications, 1998
- BisphosphonatesEuropean Journal of Cancer, 1998
- Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamineEuropean Journal of Pediatrics, 1996
- Relation between Erythropoiesis and Bone Metabolism in ThalassemiaThe New England Journal of Medicine, 1981